These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 18173943)

  • 1. Is there a role for combinations of antiplatelet agents in stroke prevention?
    Schwartz NE; Albers GW
    Curr Treat Options Neurol; 2007 Nov; 9(6):442-50. PubMed ID: 18173943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy in cerebrovascular disease: implications of Management of Artherothrombosis with Clopidogrel in High-risk Patients and the Clopidogrel for High Artherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance studies' results for cardiologists.
    Fintel DJ
    Clin Cardiol; 2007 Dec; 30(12):604-14. PubMed ID: 17847044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?
    Schwartz NE; Albers GW
    Curr Neurol Neurosci Rep; 2008 Jan; 8(1):29-34. PubMed ID: 18367036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
    Lenz T; Wilson A
    Clin Pharmacokinet; 2003; 42(10):909-20. PubMed ID: 12885264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
    Diener HC; Sacco R; Yusuf S; ;
    Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
    Skliut M; Jamieson DG
    Curr Cardiol Rep; 2008 Feb; 10(1):9-16. PubMed ID: 18416995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
    Hankey GJ
    Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
    Chaturvedi S
    Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
    Tran H; Anand SS
    JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
    Davis KA; Miyares MA; Dietrich E
    Am J Health Syst Pharm; 2015 Oct; 72(19):1623-9. PubMed ID: 26386103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives for optimizing oral antiplatelet therapy.
    Easton JD
    Cerebrovasc Dis; 2001; 11 Suppl 2():23-8. PubMed ID: 11316919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet agents for secondary prevention of stroke.
    Bernstein RA
    Curr Treat Options Cardiovasc Med; 2008 Jun; 10(3):223-8. PubMed ID: 18582411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New opportunities to optimize antithrombotic therapy for secondary stroke prevention.
    Kim AS; Easton JD
    Int J Stroke; 2019 Apr; 14(3):220-222. PubMed ID: 30722755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
    Zusman RM; Chesebro JH; Comerota A; Hartmann JR; Massin EK; Raps E; Wolf PA
    Clin Cardiol; 1999 Sep; 22(9):559-73. PubMed ID: 10486695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.